MBP and myeloid sarcoma: Similarly, subcutaneous administration of a mixture of three MBP peptides (peptides 46-64, 124–139, and 147-170), termed Xemys, in MS patients was safe, while treatment decreased the cytokines monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, and IL-7 and -2 levels, thus indicating reduced inflammation.